Clinical Trial: Myositis Interstitial Lung Disease Nintedanib Trial
Study Status: Completed
Recruit Status: RECRUITING
Condition: Myositis Associated Interstitial Lund Disease (MA-ILD)
Study Type: INTERVENTIONAL
Official Title: Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized,
Brief Summary:
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung.This study will enroll a total of 134 participants across 15 clinical sites located in the United States.A subset of participants will be…
Read more